Pier Capital LLC Has Trimmed Position in Repligen Corp (RGEN) as Stock Price Rose

Repligen Corporation (NASDAQ:RGEN) LogoInvestors sentiment increased to 1.45 in Q2 2019. Its up 0.09, from 1.36 in 2019Q1. It improved, as 18 investors sold RGEN shares while 69 reduced holdings. 41 funds opened positions while 85 raised stakes. 43.72 million shares or 9.91% more from 39.77 million shares in 2019Q1 were reported. Bb&T holds 0.01% or 6,405 shares in its portfolio. Shell Asset Mgmt Communications has 7,531 shares. The New York-based Sandler Mngmt has invested 1.17% in Repligen Corporation (NASDAQ:RGEN). Lord Abbett & Limited Liability Com owns 743,252 shares for 0.21% of their portfolio. Metropolitan Life Com holds 12,565 shares. Fred Alger Mgmt has invested 0.61% in Repligen Corporation (NASDAQ:RGEN). Legal & General Group Public Ltd Liability holds 0.01% or 112,461 shares in its portfolio. Castleark Mgmt Limited Liability Com invested in 25,820 shares. Navellier Inc holds 0.1% or 7,532 shares. Arizona State Retirement invested in 0.06% or 65,198 shares. Washington-based Parametric Portfolio Assocs Ltd Liability Corp has invested 0.01% in Repligen Corporation (NASDAQ:RGEN). Ls Inv Advsrs Limited Liability Company reported 1,555 shares. Credit Suisse Ag reported 24,029 shares. Benjamin F Edwards & reported 329 shares stake. Advsrs Preferred holds 0.01% or 450 shares in its portfolio.

Pier Capital Llc decreased its stake in Repligen Corp (RGEN) by 25.34% based on its latest 2019Q2 regulatory filing with the SEC. Pier Capital Llc sold 35,760 shares as the company’s stock rose 43.41% . The institutional investor held 105,337 shares of the biological products (no diagnostic substances) company at the end of 2019Q2, valued at $9.05 million, down from 141,097 at the end of the previous reported quarter. Pier Capital Llc who had been investing in Repligen Corp for a number of months, seems to be less bullish one the $4.11B market cap company. The stock increased 1.00% or $0.79 during the last trading session, reaching $79.8. About 375,130 shares traded. Repligen Corporation (NASDAQ:RGEN) has risen 101.69% since September 13, 2018 and is uptrending. It has outperformed by 101.69% the S&P500.

Analysts await Repligen Corporation (NASDAQ:RGEN) to report earnings on November, 7. They expect $0.20 EPS, 0.00 % or $0.00 from last year’s $0.2 per share. RGEN’s profit will be $10.31 million for 99.75 P/E if the $0.20 EPS becomes a reality. After $0.31 actual EPS reported by Repligen Corporation for the previous quarter, Wall Street now forecasts -35.48 % negative EPS growth.

More notable recent Repligen Corporation (NASDAQ:RGEN) news were published by: Seekingalpha.com which released: “Healthcare – Top 5 Gainers / Losers – Seeking Alpha” on September 09, 2019, also Fool.com with their article: “3 Stocks to Buy and Hold for Decades – The Motley Fool” published on August 28, 2019, Nasdaq.com published: “Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options – Nasdaq” on July 19, 2019. More interesting news about Repligen Corporation (NASDAQ:RGEN) were released by: Nasdaq.com and their article: “Health Care Sector Update for 09/09/2019: ACHC,ACAD,RGEN – Nasdaq” published on September 09, 2019 as well as Finance.Yahoo.com‘s news article titled: “How Many Repligen Corporation (NASDAQ:RGEN) Shares Have Insiders Sold, In The Last Year? – Yahoo Finance” with publication date: June 12, 2019.

Repligen Corporation (NASDAQ:RGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.